Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Clostridioides difficile infection (CDI) is the most common health-care-associated infection in the USA (1)
NCT02092935 - Ridinilazole vs Vancomycin & Clostridioides difficile infection (CDI) (initial) is a randomized, double-blind, and active-controlled phase II treatment trial to show non-inferiority of oral ridinilazole (200 mg every 12 hours) vs. vancomycin (125 mg every 6 hours) in 69 evaluated participants with Clostridioides difficile infection (CDI) (initial) (1).
Sustained clinical response i.e., c…